Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Venmax Drugs and Pharmaceuticals Ltd (NSE: VENMAX), ISIN INE154G01022 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
VENMAX last traded at ₹14.80 (+3.79%), with a 52-week range of ₹12.51 to ₹31.49 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 10.46%, FIIs 0.00%, DIIs 0.00%, mutual funds 0.00%.
EquiSense Score (ECS): 56/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.